| Literature DB >> 28486425 |
Jing Wang1,2, Yun Hou3,4, Delin Duan5,6,7, Quanbin Zhang8,9.
Abstract
Porphyran is a sulfate galactan in the cell wall of Porphyra. Its acid hydrolysis product, oligo-porphyran (OP), was prepared and the structure studied by electrospray ionization time-of-flight mass spectrometry (ESI-TOF-MS). This oligosaccharide was mainly composed of monosulfate-oligo-galactan, disufate-oligo-galactan, trisulfate-oligo-galactan, trisulfate oligo-methyl-galactan, and 3,6-anhydrogalactose with the degree of polymerization ranging from 1 to 8. The effects of OP were investigated in the glycerol-induced acute renal failure (ARF) model. Compared with the normal group, rats from the glycerol-induced group exhibited collecting duct and medullary ascending limb dilation and casts. The OP-treated group exerted a protective effect against glycerol-induced changes. The results showed that the administration of OP markedly decreased mortality in female ARF rats. For male ARF rats, all of which survived, OP significantly decreased the blood urea nitrogen and serum creatinine levels. Ion levels in plasma and urine were significantly changed in ARF rats, whereas OP treatment almost recovered ion levels back to normal. This study showed a noticeable renal morphologic and functional protection by OP in glycerol-induced ARF rats.Entities:
Keywords: acute renal failure; gender difference; oligo-porphyran; sulfated galactan
Mesh:
Substances:
Year: 2017 PMID: 28486425 PMCID: PMC5450541 DOI: 10.3390/md15050135
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
The chemical analysis of OP.
| Sample | Mw (Kda) | Sulfate Group (%) | Galactose (%) | 3,6-anhydrogalactose (%) |
|---|---|---|---|---|
| OP | 1.43 | 16.90 ± 0.51 | 59.93 ± 1.44 | 6.45 ± 0.17 |
Figure 1Chromatography of eluted OP on DEAE-sepharose CL-6B chromatography.
Figure 2The degree of polymerization of OP and its fractions tested by HPLC.
Figure 3ESI-TOF-MS spectra of the fractions F1–F4 in a negative mode. All of the main peaks correspond to [M−nH]− of each individual sulfated galactan oligomer.
Figure 4Mortalities of female rats in experimental groups. Normal: normal rats without acute renal failure (ARF); NC: negative control group (ARF rats); PC: positive control group (ARF + dexamethasone 0.1 mg/kg BW per day); OP10: ARF rats treated with oligo-porphyran (10 mg/kg body weight per day); OP30: ARF rats treated with oligo-porphyran (30 mg/kg body weight per day).
Levels of BUN and SCR in the blood of experimental groups after injection 50% Glycerol for 48 h.
| Gender | Index | Normal | NC | PC | OP10 | OP30 |
|---|---|---|---|---|---|---|
| Male | BUN (nmol/L) | 7.73 ± 0.27 | 11.48 ± 1.23 ** | 12.27 ± 0.74 ** | 11.96 ± 1.08 ** | 12.32 ± 2.11 ** |
| SCR (μmol/L) | 15.32 ± 0.74 | 26.72 ± 3.18 ** | 24.48 ± 1.64 ** | 27.11 ± 2.54 ** | 26.22 ± 1.71 ** | |
| Female | BUN (nmol/L) | 6.91 ± 0.54 | 13.44 ± 0.88 ** | 13.18 ± 0.68 ** | 12.64 ± 0.67 ** | 14.97 ± 1.29 ** |
| SCR (μmol/L) | 13.94 ± 1.05 | 25.64 ± 1.94 ** | 24.99 ± 0.96 ** | 26.70 ± 1.27 ** | 26.02 ± 1.13 ** |
Normal: normal rats without acute renal failure (ARF); NC: negative control group (ARF rats); PC: positive control group (ARF + dexamethasone 0.1 mg/kg BW per day); OP10: ARF rats treated with oligo-porphyran (10 mg/kg body weight per day); OP30: ARF rats treated with oligo-porphyran (30 mg/kg body weight per day); ** p < 0.01 compared with the Normal group. Statistical analysis was performed using ANOVA. Data are presented as mean ± S.D. (n = 7 in male rats, n = 4–7 in female rats).
Figure 5Blood urea nitrogen (BUN, Figure 5A) and serum creatinine (SCR, Figure 5B) levels of experimental groups. Normal: normal rats without acute renal failure (ARF); NC: negative control group (ARF rats); PC: positive control group (ARF + dexamethasone 0.1 mg/kg BW per day); OP10: ARF rats treated with oligo-porphyran (10 mg/kg body weight per day); OP30: ARF rats treated with oligo-porphyran (30 mg/kg body weight per day); * p < 0.05, ** p < 0.01 compared with NC. Data are presented as mean ± S.D. (n = 7).
Levels of protein, potassium ions, sodium ions, chlorine ions, and calcium ions in the blood (A) and urine (B) of experimental groups.
| Normal | 32.95 ± 2.27 | 5.48 ± 0.63 | 148.27 ± 0.81 ** | 106.43 ± 2.00 ** | 2.52 ± 0.13 |
| NC | 33.19 ± 1.34 | 6.27 ± 2.22 | 144.53 ± 2.04 | 99.41 ± 3.84 | 2.54 ± 0.23 |
| PC | 36.96 ± 1.79 | 7.03 ± 3.04 | 145.68 ± 1.98 | 97.04 ± 3.66 | 2.66 ± 0.19 |
| OP10 | 32.84 ± 1.55 | 5.46 ± 0.49 | 144.24 ± 1.66 | 103.70 ± 1.99 * | 2.49 ± 0.10 |
| OP30 | 32.82 ± 1.53 | 5.12 ± 0.24 | 143.63 ± 1.35 | 103.55 ± 0.54 * | 2.56 ± 0.07 |
| Normal | 0.41 ± 0.19 | 64.56 ± 10.27 * | 228.48 ± 27.75 ** | 338.58 ± 68.46 ** | 3.67 ± 2.06 |
| NC | 0.29 ± 0.22 | 47.13 ± 10.60 | 74.07 ± 33.67 | 113.93 ± 54.31 | 5.00 ± 2.58 |
| PC | 0.62 ± 0.57 | 42.88 ± 17.50 | 43.33 ± 31.89 * | 71.49 ± 66.48 | 2.16 ± 2.10 * |
| OP10 | 0.25 ± 0.12 | 62.19 ± 5.22 ** | 185.21 ± 29.06 ** | 278.41 ± 60.09 ** | 3.78 ± 2.40 |
| OP30 | 0.29 ± 0.12 | 67.45 ± 4.19 ** | 201.38 ± 61.62 ** | 282.80 ± 054 ** | 4.09 ± 1.01 |
Normal: normal rats without acute renal failure (ARF); NC: negative control group (ARF rats); PC: positive control group (ARF + dexamethasone 0.1 mg/kg BW per day); OP10: ARF rats treated with oligo-porphyran (10 mg/kg body weight per day); OP30: ARF rats treated with oligo-porphyran (30 mg/kg body weight per day); * p < 0.05, ** p < 0.01 compared with NC. Statistical analysis was performed using ANOVA. Data are presented as mean ± S.D. (n = 7).
Figure 6Histopathological studies on renal tissues of rats in the NC group (A,B) and OP10 (C,D) group. (A,C): cortex; (B,D): medulla. NC group: negative control group (acute renal failure rats); OP10 group: acute renal failure rats treated with oligo-porphyran (10 mg/kg body weight per day).
Mobile phase gradient.
| Time (min) | Acetonitrile (%) | Buffer (%) |
|---|---|---|
| 0 | 80 | 20 |
| 30 | 40 | 60 |
| 40 | 10 | 90 |